Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma

Eun Young Kim; Eun Na Cho; Heae Surng Park; Arum Kim; Ji Young Hong; Seri Lim; Jong Pil Youn; Seung Yong Hwang; Yoon Soo Chang; Kim, Eun Young; Cho, Eun Na; Park, Heae Surng; Kim, Arum; Hong, Ji Young; Lim, Seri; Youn, Jong Pil; Hwang, Seung Yong; Chang, Yoon Soo
January 2016
BMC Cancer;1/18/2016, Vol. 16, p1
Academic Journal
journal article
Background: Biopsy for lung cancer diagnosis is usually done at a single site. But it is unclear that genetic information at one biopsy site represents that of other lesions and is sufficient for therapeutic decision making. Methods: Non-synonymous mutations and insertions/deletions of 16 genes containing actionable mutations, and intron 2 deletion polymorphism of Bcl2-like11 were analyzed in 41 primary tumor and metastatic lymph node (L/N) matched, pStage IIA ~ IIIA non-small cell lung cancer (NSCLC) samples using a next generation sequencing based technique. Results: A total of 249 mutations, including 213 non-synonymous mutations, 32 deletions, and four insertions were discovered. There was a higher chance of discovering non-synonymous mutations in the primary tumors than in the metastatic L/N (138 (64.8%) vs. 75 (35.2%)). In the primary tumors, 106 G > A:C > T transitions (76.8%) of 138 non-synonymous mutations were detected, whereas in the metastatic L/N, 44 (58.7%) of 75 were discovered. A total 24 (11.3%) out of 213 non-synonymous mutations were developed in the context of APOBEC signature. Of those, 21 (87.5%) was detected in the primary tumors and 4 (16.7%) was detected in the metastatic L/N. When the mutation profiles between primary tumor and metastatic L/N were compared, 13 (31.7%) of 41 cases showed discrepant mutation profile. There were no statistically significant differences in disease free survival and overall survival between groups showing identical mutation profiles and those with discrepancy between primary and metastatic L/N. Conclusions: Genetic heterogeneity between the primary and L/N metastatic lesions is not infrequent finding to consider when interpreting genomic data based on the result of one site inspection. A large prospective study may be needed to evaluate the impact of genetic heterogeneity on the clinical outcomes of NSCLC patients.


Related Articles

  • The molecular approach to diagnosis in lung cancer. Moore, David A.; Le Quesne, John PC // British Journal of Hospital Medicine (17508460);May2015, Vol. 76 Issue 5, pC74 

    The article discusses lung cancer diagnosis using emerging technologies, as well as its role in providing better understanding of tumour biology. Topics discussed include technological advancements in lung cancer subclassification including antifolate chemotherapy and the range of genomic...

  • Modified Histologic Classification as a Prognostic Factor in Pulmonary Adenocarcinoma. Hwang, Ilseon; Park, Keon Uk; Kwon, Kun Young // International Journal of Surgical Pathology;May2014, Vol. 22 Issue 3, p212 

    Background. The histologic pattern of pulmonary adenocarcinoma is highly heterogeneous and considered to be an important prognostic factor. The predominant histologic pattern is emphasized in the 2011 International Association for the Study of Lung Cancer, American Thoracic Society, and European...

  • Advancing Personalized Cancer Medicine in Lung Cancer. Macconaill, Laura E. // Archives of Pathology & Laboratory Medicine;Oct2012, Vol. 136 Issue 10, p1210 

    Although improvements in genomic technologies during the past decade have greatly advanced our understanding of the genomic alterations that contribute to lung cancer, and the disease has (to a degree) become a paradigm for individualized cancer treatment in solid tumors, additional challenges...

  • Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. Offin, Michael; Chabon, Jacob J.; Razavi, Pedram; Isbell, James M.; Rudin, Charles M.; Diehn, Maximilian; Li, Bob T. // Journal of Oncology;3/14/2017, p1 

    Genetic sequencing of malignancies has become increasingly important to uncover therapeutic targets and capture the tumor’s dynamic changes to drug sensitivity and resistance through genomic evolution. In lung cancers, the current standard of tissue biopsy at the time of diagnosis and...

  • MicroRNAs level as an initial screening method for early-stage lung cancer: a bivariate diagnostic random-effects meta-analysis. Wen-Jie He; Wen-Hui Li; Bo Jiang; Yu-Feng Wang; Yao-Xiong Xia; Li Wang // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 8, p12317 

    Accumulating studies suggested that microRNAs (miRNAs) can have high diagnostic value as a non-invasive and cost-effective procedure with high sensitivity and specificity in the detection of early-stage lung cancer. However, there is inconsistency observed in the results of relevant studies....

  • Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA. Ikushima, Hiroaki; Sakatani, Toshio; Usui, Kazuhiro // Oncology;2020, Vol. 98 Issue 1, p23 

    Background: Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), is effective against EGFR-mutated non-small cell lung carcinoma resistant to first- or second-generation EGFR-TKIs in patients in whom an EGFR T790M mutation has been detected....

  • Frequent Mutations in EGFR, KRAS and TP53 Genes in Human Lung Cancer Tumors Detected by Ion Torrent DNA Sequencing. Cai, Xin; Sheng, Jianhui; Tang, Chuanning; Nandakumar, Vijayalakshmi; Ye, Hua; Ji, Hong; Tang, Haiying; Qin, Yu; Guan, Hongwei; Lou, Feng; Zhang, Dandan; Sun, Hong; Dong, Haichao; Zhang, Guangchun; Liu, Zhiyuan; Dong, Zhishou; Guo, Baishuai; Yan, He; Yan, Chaowei; Wang, Lu // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Lung cancer is the most common malignancy and the leading cause of cancer deaths worldwide. While smoking is by far the leading cause of lung cancer, other environmental and genetic factors influence the development and progression of the cancer. Since unique mutations patterns have been...

  • Low expression of dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin-related protein in lung cancer and significant correlations with brain metastasis and natural killer cells. Liu, Xiaoli; Zhang, Hua; Su, Lijie; Zuo, Yunfei; Yang, Peng; Xin, Zhiqiang; Zou, Junwei; Ren, Shuangyi // Molecular & Cellular Biochemistry;Sep2015, Vol. 407 Issue 1/2, p151 

    Dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin-related protein (DC-SIGNR) is a type II transmembrane protein which has been reported to bind a variety of pathogens as well as participate in immunoregulation. But the association between the level of DC-SIGNR and lung...

  • Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology. Ou, Sai-Hong Ignatius; Bartlett, Cynthia Huang; Mino-Kenudson, Mari; Cui, Jean; Iafrate, A. John // Oncologist;Nov2012, Vol. 17 Issue 11, p1351 

    Crizotinib, an ALK/MET/ROS1 inhibitor, was approved by the U.S. Food and Drug Administration for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) in August 2011, merely 4 years after the first publication of ALK-rearranged NSCLC. The crizotinib...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics